Literature DB >> 3684830

Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo.

H Sinzinger1, J O'Grady, P Fitscha.   

Abstract

The effects of infusions of prostaglandin E1 (PGE1) on platelet deposition at atherosclerotic sites in vivo in man have been examined. Thirteen patients with atherosclerotic vascular disease received intravenous PGE1 25 mg/kg/min for 6 hours daily for 5 days. Prostaglandin E1 had no effect on platelet uptake at atherosclerotic sites but prolonged platelet half-life significantly (P less than 0.001).

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3684830      PMCID： PMC2428153          DOI： 10.1136/pgmj.63.738.245

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN： 0032-5473            Impact factor:   2.401


  14 in total

1.  Intravenous prostaglandin E1 in severe peripheral vascular disease.

Authors:  L A Carlson; A G Olsson
Journal:  Lancet       Date:  1976-10-09       Impact factor: 79.321

Review 2.  Clinical pharmacology and potential of prostacyclin.

Authors:  P J Lewis; C T Dollery
Journal:  Br Med Bull       Date:  1983-07       Impact factor: 4.291

3.  A multi-clinical double blind study with PGE, (alpha-cyclodextrin clathrate) in patients with ischemic ulcer of the extremities.

Authors:  S Sakaguchi; A Kusaba; Y Mishima; K Kamiya; A Nishimura; K Furukawa; S Shionoya; M Kawashima; T Katsumura; A Sakuma
Journal:  Vasa       Date:  1978       Impact factor: 1.961

4.  Effect of intra-arterial infusion of PGE1 in patients with severe ischemia of lower extremity.

Authors:  G K Sethi; S M Scott; T Takaro
Journal:  J Cardiovasc Surg (Torino)       Date:  1980 Mar-Apr       Impact factor: 1.888

5.  Efficacy of prostaglandin E1 in the treatment of lower extremity ischemic ulcers secondary to peripheral vascular occlusive disease. Results of a prospective randomized, double-blind, multicenter clinical trial.

Authors:  J J Schuler; D P Flanigan; J W Holcroft; J J Ursprung; J S Mohrland; J Pyke
Journal:  J Vasc Surg       Date:  1984-01       Impact factor: 4.268

6.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation.

Authors:  S Moncada; R Gryglewski; S Bunting; J R Vane
Journal:  Nature       Date:  1976-10-21       Impact factor: 49.962

7.  Preliminary experience with prostaglandins E1 and I2 in peripheral vascular disease.

Authors:  B J Pardy; J D Lewis; H H Eastcott
Journal:  Surgery       Date:  1980-12       Impact factor: 3.982

8.  Epoprostenol (prostacyclin) decreases platelet deposition on vascular prosthetic grafts.

Authors:  H Sinzinger; J O'Grady; M Cromwell; R Hofer
Journal:  Lancet       Date:  1983-06-04       Impact factor: 79.321

9.  Successful therapy of advanced arteriosclerosis obliterans with prostacyclin.

Authors:  A Szczeklik; R Nizankowski; S Skawinski; J Szczeklik; P Gluszko; R J Gryglewski
Journal:  Lancet       Date:  1979-05-26       Impact factor: 79.321

10.  Detrimental effect of high-dose prostaglandin E1 in the treatment of ischemic ulcers.

Authors:  R S Rhodes; S E Heard
Journal:  Surgery       Date:  1983-06       Impact factor: 3.982
View more
  2 in total

1.  Stabilization of endothelial lining and decrease in circulating endothelial cells--one mechanism underlying the clinical action of PGE1?

Authors:  H Sinzinger; I Virgolini; P Fitscha; F Rauscha; J Kaliman
Journal:  Br J Clin Pharmacol       Date:  1988-06       Impact factor: 4.335

2.  Horizontal acquisition of a patchwork Calvin cycle by symbiotic and free-living Campylobacterota (formerly Epsilonproteobacteria).

Authors:  Adrien Assié; Nikolaus Leisch; Dimitri V Meier; Harald Gruber-Vodicka; Halina E Tegetmeyer; Anke Meyerdierks; Manuel Kleiner; Tjorven Hinzke; Samantha Joye; Matthew Saxton; Nicole Dubilier; Jillian M Petersen
Journal:  ISME J       Date:  2019-09-27       Impact factor: 10.302
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.